Skip to content
Info
Flow
Home
Markets
News
Square
InfoAI
Search markets, news, or ask InfoAI
⌘K
Log in
Home
News
Markets
Square
Me
FDA approves Retatrutide this year? | Yes / No 2.6% | InfoFlow – Leveraged Prediction Market
F
Tech
FDA approves Retatrutide this year?
2.6
%
Market probability
$595.2K
Vol
Settles Jan 1
1H
6H
1D
1W
1M
ALL
Order book
Yes
No
Price
Size
Total
Mid
—
Settlement rules
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee…
More
▾
Holders
0
Activity
0
Comments
0
